Tejara Capital Ltd Invests $2.27 Million in QuidelOrtho Corporation $QDEL

Tejara Capital Ltd bought a new stake in QuidelOrtho Corporation (NASDAQ:QDEL) in the 2nd quarter, Holdings Channel.com reports. The firm bought 129,890 shares of the company’s stock, valued at approximately $2,275,000.

Other institutional investors have also recently bought and sold shares of the company. BlackRock Inc. bought a new stake in QuidelOrtho in the second quarter valued at approximately $196,212,000. Deutsche Bank AG acquired a new position in shares of QuidelOrtho during the 2nd quarter worth approximately $1,616,000. Rice Hall James & Associates LLC bought a new stake in QuidelOrtho in the 2nd quarter valued at $18,628,000. Monaco Asset Management SAM acquired a new stake in QuidelOrtho during the 2nd quarter valued at $1,138,000. Finally, Bank of New York Mellon Corp bought a new position in QuidelOrtho in the 2nd quarter valued at about $7,720,000. Institutional investors and hedge funds own 99.00% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Wall Street Zen raised QuidelOrtho from a “sell” rating to a “hold” rating in a report on Sunday, June 28th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of QuidelOrtho in a report on Friday, July 17th. UBS Group reiterated a “neutral” rating and set a $12.00 price objective on shares of QuidelOrtho in a research report on Thursday, May 7th. Zacks Research downgraded QuidelOrtho from a “hold” rating to a “strong sell” rating in a report on Wednesday, August 12th. Finally, Citigroup upped their price target on shares of QuidelOrtho from $13.00 to $18.00 and gave the company a “neutral” rating in a research note on Wednesday, July 8th. Three research analysts have rated the stock with a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Reduce” and a consensus target price of $13.62.

QuidelOrtho Price Performance

Shares of NASDAQ:QDEL opened at $14.85 on Friday. The company has a current ratio of 1.39, a quick ratio of 0.76 and a debt-to-equity ratio of 1.43. The stock has a market capitalization of $1.02 billion, a PE ratio of -0.96 and a beta of 0.68. The firm has a 50 day moving average of $15.81 and a 200-day moving average of $16.53. QuidelOrtho Corporation has a 12 month low of $9.92 and a 12 month high of $35.58.

QuidelOrtho (NASDAQ:QDEL) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.18. QuidelOrtho had a negative net margin of 39.20% and a positive return on equity of 4.88%. The business had revenue of $630.90 million for the quarter, compared to analysts’ expectations of $618.72 million. During the same period last year, the firm posted $0.12 earnings per share. The firm’s quarterly revenue was up 2.8% compared to the same quarter last year. QuidelOrtho has set its FY 2026 guidance at 0.650-0.900 EPS. On average, equities research analysts predict that QuidelOrtho Corporation will post 0.75 EPS for the current fiscal year.

QuidelOrtho Profile

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.